October 2025 Newsletter

October 2025 Newsletter

FUJIFILM Biotechnologies is proud to be an innovative CDMO partner, seamlessly guiding our customers though their journey of creating life-impacting medicines from initial process development stages through to full commercial supply. Catch up on our latest news and insights below.

 Lars Petersen named ‘CEO of the Year’

We are thrilled to announce that Lars Petersen won ‘CEO of the Year’ this week at the CPHI Pharma Awards 2025, in recognition of his transformational leadership within the CDMO industry.

Since taking the helm as CEO two years ago, Lars has led FUJIFILM Biotechnologies through the current landscape of geopolitical challenges and vulnerabilities in the global supply chain – addressing this by implementing the industry’s largest interconnected modular network of biomanufacturing facilities, which we call ‘kojoX™’.

This revolutionary approach to supply continuity is resonating with global pharma companies, as seen in several new long-term deals that Lars helped bring to FUJIFILM Biotechnologies.

He has also been the stimulus to drive billions of dollars in investments across our network to create an interconnected and agile ecosystem that can accelerate the delivery of life-changing medicines to our partners and patients worldwide.

In the below Molecule to Market podcast interview, Lars reflects on his background, career, People First leadership mindset, and exciting plans for the future.

He has done all this while advocating for trust-based partnerships with employees, customer and industry, and pioneered a “people first” culture within the organization.

Looking to develop or optimize your process? Explore our process development services

Learn More →

Learn how in silico strategies can enhance efficiency in monoclonal antibody bioprocess development

Download the White Paper →

We can partner with you to develop a suitable formulation for your drug substance or drug product

Discover our formulation development approach →

NOW TRENDING

In the News

• At our Hillerød commercial-scale biologics manufacturing site, 100 percent of the electricity needs are now covered by solar power through Power Purchase Agreements (PPA). This reflects our strong commitment to sustainability and our Partners for the Planet strategy. Read more from the recent BioProcess International article →
  
  
• We recently announced a significant expansion of our global partnership with argenx SE, a global immunology company. This marks our first global end-to-end program in support of a customer utilizing our kojoX modular network of facilities, with manufacturing of argenx’s drug substance for efgartigimod expanding from our Denmark site to our Holly Springs, North Carolina, site in 2028. Read the story on Fierce Pharma →
  
  
• Our Chief Operating Officer, Maja Pedersen, has been named to the Profiles in Leadership Journal’s 2025 Women Worth Watching list. Her dedication to prioritizing people and advancing transformative science truly reflects our Partners for Life strategy. Read more →
  
  
• At CPHI 2025, our VP, Commercial Development – Biologics, Mark Santos, shared his insights on trends affecting the industry. Mark discusses the topic of preparing for commercial launch, the strategies for getting crucial programs to market effectively, and how we make ourselves agile, efficient and flexible for our customers and the patients we are all trying to serve. Watch the video →